Takeaway

• Though it lowered triglyceride levels, pemafibrate did not lower cardiovascular risk in patients with diabetes and hypertriglyceridaemia.
• This trial adds to other recent trials that suggest that, in patients already receiving statin therapy, adding pemafibrate does not further reduce risk.

Why this matters

• High triglycerides are associated with higher...